China's National Medical Products Administration has introduced new Implementation Measures for the Protection of Drug Trial Data, establishing a dual-track system of patent and data protection for pharmaceuticals. The measures grant data exclusivity periods ranging from 3 to 6 years for innovative drugs, improved new drugs, and generic drugs, with significant changes from earlier drafts including removal of time-gap reductions and extended protection for improved formulations.
Spruson & Ferguson Lawyers
